Sylvia S. Gayle

Targeting BCL-xL improves the efficacy of bromodomain and extra-terminal protein inhibitors in triple-negative breast cancer by eliciting the death of senescent cells

Sylvia S. Gayle, Jennifer M. Sahni, Bryan M. Webb et al. · Journal of Biological Chemistry · 2018 · 59 citations · Full text

Medicine, Cancer Biology, Oncology +12

Bromodomain and Extraterminal Protein Inhibition Blocks Growth of Triple-negative Breast Cancers through the Suppression of Aurora Kinases

Jennifer M. Sahni, Sylvia S. Gayle, Kristen L. Weber-Bonk et al. · Journal of Biological Chemistry · 2016 · 56 citations · Full text

Medicine, Molecular Biology, Oncology +15

Pharmacologic Inhibition of mTOR Improves Lapatinib Sensitivity in HER2-Overexpressing Breast Cancer Cells with Primary Trastuzumab Resistance

Sylvia S. Gayle, Samuel L.M. Arnold, Ruth O’Regan et al. · Anti-Cancer Agents in Medicinal Chemistry · 2012 · 50 citations · Full text

Medicine, Oncology, Pharmacology +17

Mitotic Vulnerability in Triple-Negative Breast Cancer Associated with LIN9 Is Targetable with BET Inhibitors

Jennifer M. Sahni, Sylvia S. Gayle, Bryan M. Webb et al. · Cancer Research · 2017 · 31 citations · Full text

Medicine, Cancer Biology, Oncology +17

MEK Inhibition Increases Lapatinib Sensitivity Via Modulation of FOXM1

Sylvia S. Gayle, Robert C. Castellino, Meghan C. Buss et al. · Current Medicinal Chemistry · 2013 · 24 citations · Full text

Medicine, Cancer Biology, Pharmacology +17